Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

GVAX induces immune responses in prostate cancer patients

May 21, 1998

Herceptin: promising phase III results reported at ASCO

May 20, 1998

Neurocrine Biosciences initiates clinical-stage development of IL-4 fusion toxin

May 19, 1998

Leuvectin proceeds to phase II for renal cell carcinoma

May 19, 1998

Antigenics receives patent protection for HSP-based cancer immunotherapy

May 15, 1998

Bexxar: encouraging interim phase III data reported

May 14, 1998

DAB389IL-7, a novel fusion protein for the specific elimination of IL-7 receptor-positive cells

May 12, 1998

Patient enrollment begins for U.S. trial of Maxamine in malignant melanoma

May 11, 1998

Multikine clinical trials update

May 11, 1998

Genentech files for marketing approval of Herceptin

May 5, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...